Cardiawave SA has appointed of Olivier Pierron as its new chief executive officer. The company is developing Valvosoft, a breakthrough technology that allows for the remote application of a focused therapeutic ultrasound beam to restore valve function in patients with aortic stenosis (AS).
With more than 25 years of experience in cardiovascular therapies, Pierron brings to Cardiawave expertise in the development and international commercialisation of new medical technologies at a crucial time in the company’s growth, following the announcement of positive clinical trial results.
Pierron, said: “The approach developed by Cardiawave is unique and complements the existing range of cardiology treatments. Being entirely non-invasive, it expands the treatment options of patients suffering from severe symptomatic aortic valve stenosis. I am very honoured to be joining this visionary team and to be working with them to bring this disruptive solution to market, in order to treat the largest number of people as quickly as possible.
“Cardiawave’s technology represents a major step forward, one that is acknowledged by the international medical community, and our clinical results are very promising. I am determined to make this innovation a success in our various markets.”
Pierron will be tasked with deploying Valvosoft in the European market, starting clinical trials in the USA under premarket approval, strengthening strategic partnerships to bolster Cardiawave’s international footprint, and leading its series B funding in order to accelerate its development.
Cardiawave has recently filed its CE mark application and completed the enrolment of 60 patients in the Valvosoft Pivotal study, taking the total number of severe symptomatic calcific aortic stenosis patients being treated to 100, across 12 research centres in four European countries. The six-month results of first-in-human studies have been published in The Lancet.
